NATIONAL INSTITUTES OF HEALTH

Eisai announces COFEPRIS approval of Leqembi (lecanemab) for early Alzheimer's disease in Mexico, marking the first treatment to reduce disease progression and cognitive decline by targeting Aβ protofibrils and plaques. Leqembi is also approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE, and Great Britain. The approval is based on Phase 3 Clarity AD trial data, with an estimated 1.3 million Alzheimer's patients in Mexico. The drug is a result of a collaboration between BioArctic and Eisai, with BioArctic responsible for commercialization in the Nordic region pending European approval.

Cedars-Sinai study shows increasing racial and ethnic diversity in clinical trials through culturally sensitive language, digital tools, and focus group insights, leading to significant rise in Black and Hispanic participant recruitment.

BioArctic's partner Eisai announces COFEPRIS approval of Leqembi for early Alzheimer's disease in Mexico. Leqembi reduces Aβ protofibrils and plaques, slowing cognitive decline. It's also approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE, and Great Britain. Based on Phase 3 Clarity AD trial data, Leqembi met primary and secondary endpoints. Collaboration with BioArctic began in 2005, with Eisai leading clinical development and commercialization.

Ralph R. Weichselbaum, MD, appointed University of Chicago Health System leader for Radiation and Cellular Oncology, expanding radiation therapy to patients in Chicago’s suburbs and Northwest Indiana. UChicago Medicine’s cancer program ranked No. 1 in Illinois, constructing the state’s first freestanding cancer care facility, the AbbVie Foundation Cancer Pavilion, set to open in 2027. Weichselbaum continues as Chair of the Department of Radiation and Cellular Oncology, overseeing Illinois’ largest integrated academic program and research collaborations, recognized for contributions to radiation oncology and cancer research.